of yohimbine on, in man Age, effect on response of heart to

Transcription

O031-6997/83/3504-0325$02.OO/O
PHARMACOLOGICAL
REVIEWS
Copyright
© 1984 by The American
Society
for Pharmacology
and
Experimental
Vol. 35, No. 4
Printed
in U.S.A.
Therapeutics
Index
PHARMACOLOGICAL
Volume
REVIEWS
35
1983
Acetylcholine
fl-adrenergic
P and,
substance
effects
bine,
adrenal
medulla
central
nervous
intestinal
neurons,
sympathetic
119
119
mesocortical
Adenylate
cyclase
analysis
heterologous
opioids
and,
and,
withdrawal
of,
desensitization
of, 5
11
of, 6
cord,
232
for
(fig.),
8
acids,
AMP,
cyclic-
relative
animals,
305
(table),
305
P
substance
responses,
(table),
fl-Adrenergic
and
effects
on,
by
effect
heart
on
differential
response
to glucagon,
cell
of yohimbine
effects
binding
assays
of, during
membrane
during
long-term
form
linked
on,
in
agonist-induced
exposure
of, during
cellular
for
man
desen-
Autonomic
reflexes,
Autonomic
system,
receptors,
receptor(s),
desen-
(fig.),
of,
during
studies
23
agonist-induced
before
desensitization
recognition
in radioligand
smooth
studies
to define,
use
by
(table),
shown
opioids
for
and,
study
of,
143
in vitro,
on,
154
(table),
156
(fig.)
72;
71
73;
(table),
coverslip
film,
73
method,
use
localization
by
(fig.),
localization
by
(table),
73
73
of,
subtypes,
P
of heart to glucagon,
80
80
effects,
pupils,
on
morphine-like
in man,
drugs
(table),
suppression
and,
monkeys
(table),
analgesic
precipitation
and
men
dependence
295
and
subjective
effects
produced
Blood,
Blood
of abstinence
and
in
morphine-depend-
cyclazocine-dependent
dogs
studies,
(table),
substance
pressure,
opioid
306
shown
desensitization
of
fi-adrenergic
by
intact
cell
binding
255
255
of selected
(fig.),
capacity
in rhesus
results
in
limited
P in, 113
yohimbine
effects
on,
36
monkeys
access
(table),
substitution
36
procedures
147
receptors
by
distribution
receptor
of mesocortical
39
in (monkey),
substitution
Pharmacology
Brain
307
suppression
H. Roth.
53
opioids,
self-administration
303
and
opiates,
Benzomorphan(s)
chemical
structures
294
Robert
neurons,
microelectrophoretic
194
121
J., and
dopamine
ganglia
physical
cardiovascular
antagonist,
Michael
intravenous
239
antagonists
during,
during
78
of,
multiple,
148
Agonist(s)
analysis
by,
69
and
Basal
probe
primary,
Age, effect on response
-induced
influence
effects
brain,
Bannon,
163
muscle,
terminals,
ent
receptor
19
of, 5
145
of,
binding
a pharmacological
by
yohimbine
yohimbine
in the
substance
effects
of$-adrenergic
Baclofen
of yohimbine
Afferent
analysis
desensitization,
tritium-sensitive
13
cyclase,
yohimbine
vascular
agonist
294
binding,
modification
catecholamine-
subtypes
yohimbine,
and
analgesics
future
labeled
a-Adrenoreceptor
use
agonists,
296
70
opiate
opioid
to catecholamines,
catecholamine-induced
processing
desensitization
preparations,
adenylate
Narcotic
effects,
cell
emulsion-coated
model
cell-free
(table),
289
intact
17
specific
in
partial
dogs
123
See
agonist-induced
20
hypothetical
analgesics,
and
man
effects,
narcotic.
195
19
processing
in
P
in
Autoradiography
intact
sitization,
of narcotic
cardiovascular
165
sitization,
change
potency
narcotic,
acetylcholine
receptor(s)
analysis,
of, 5
195
Antagonists
syndrome
agents,
in responsiveness
of,
antagonist,
Assays,
blocking
302
in spinal
changes
substance
neurons,
in man,
transmitters
production
13
119
a-Adrenergic
effects,
Amino
Analgesia
model
abstinence
Adrenergic
306
294
system,
agonist-induced
195
of,
and
yohim-
293
Analgesics,
medulla
cellular
studies,
studies
respiration,
242
in man
by
306
substitution
substitution
61
studies
opioids,
blocked
152
suppression
glucagon
preparations,
Addiction
to,
desensitization,
structure
activation
in cell-free
response
56
receptor
hormonal
(table),
suppresSion
subjective
dopamine-sensitive,
systems
strong,
cardiovascular
system
agonist-induced
catecholamine-responsive,
glucagon
in in vitro
5
release
partial,
233
dopamine
during
of,
cyclase,
neurotransmitter
effects on
119
cord,
receptor-linked,
9-adrenergic
of
N-Allylnormetazocine
ganglia,
in spinal
ACTHI24,
119
system,
wall,
transmitter
Adrenal
inhibition
on
adenylate
receptor-linked
-induced
119
assays
of
ergic
19
lesions,
325
75
receptor
neuronal
response
autoradiography
nigrostriatal,
systems
of mesocortical
(table),
mesolimbic,
in,
and
71
mesocortical
schematic
diagram
dopamine
system,
dopamin-
(fig.),
61
55
326
INDEX
Brain
Cortex
stem
lower,
P
substance
microinjection
of
studies,
raphe
neurones,
dorsal,
in,
and
cerebral
responses
of
lamina
dopaminergic
V spinal
249
dopamine
250
and
of,
firing
formation,
partial
of action
of opiates,
247
uptake
agonist,
317
of
system,
294
in
glucagon
ions,
anatomy
302
man,
effect
on
glucagon,
effects,
Carbohydrate
excretion
cardiac
on
substance
metabolism,
Cardiac
arrhythmias,
Cardiac
contractility,
Cardiac
oxygen
of,
glucagon
effects
of mesocortical
influence
on,
ions,
and,
205
addiction
consumption,
on,
cyclase
processing
sure
-induced
of $-adrenergic
tissue
exposed
of j3-adrenergic
to,
receptor-linked
ade-
5
to,
in
general
properties,
physiological
receptors
of
during
long-term
receptors
fl-adrenergic
294
by rats
and
localization
on
during,
17
of, 23
cyclase,
effects,
lesion
6
processing
in,
of$.adrenergic
receptors
15
in
165;
receptors
in (rat)
(fig.),
74
122
(table),
166
Choleresis,
See
Cortex,
substance
P,
90;
on,
form
adenylate
of -adrenergic
significance
of, 8
cell
binding
assays
cyclase,
5
receptors
during,
of the
lesion
adenylate
heterologous
and
in,
15
cyclase
analysis
homologous,
during,
distinction
11
between
in
intact
12
13
effect
(table),
92
Diencephalon,
261
on
effects
kidney
on,
substance
113
186
in, 91
(DOPAC),
acid
brain,
in,
P concentration
Dihydroxyphenylacetic
cerebral
function
148
dopamine
metabolite,
in
56
Diprenorphine
effects
on
respiration,
293
Dopamine
glucagon
and,
181
agonists
glucagon
substance
effects
184
on,
response
in,
107
cells,
relationship,
function,
116
involvement
of
opiate
effects
to,
opiate-induced,
blood
response
to,
58
mesocortical
dopamine
system
in,
levels
(table),
mesocortical,
drugs,
in cortex,
rates,
relationship
58
62
57
of, in cortex,
55
metabolites
suggestions
Convulsions,
of
depletion
63
Consciousness,
Contributors,
antagonists,
to dopaminergic
properties
88
on,
structure-activity
Cognitive
and
autoreceptors
P
distribution
flow,
glucagon
cell
9
overview,
yohimbine
Circulation
pulmonary,
17
of, 23
22
heterologous,
glucagon
222
in,
action
intact
Diabetes
in, 94
peptides,
P, distribution
by
receptor-linked
hormone-specific,
P concentration
of opioid
cortex.
to other
300
receptor
membrane
heterologous,
opioid
of generalization
cyclic-
9-adrenergic
overview,
analogues,
substance
substance
degree
catecholamine-specific
222
physiology
monkeys,
fl-adrenergic
studies,
yohimbine,
305
19
physiological
properties
of
P
63
catecholamine-induced
117
opioid
Cerebellum,
of
of the
of,
structure
system
substance
relationship
55
man,
AMP,
localization
P and,
nervous
in
See
change
of the
Caudate-putamen,
its
304
292
respiration,
subjective
analysis
22
opiates,
(table),
during,
model
for cellular
(fig.),
23
overview,
and
expo-
desensitization
substance
effects,
discrimination
8
significance
hypothetical
during
projection
agonist-induced
form
adenylate
-specific
56
Desensitization
membrane
responsive
in,
in animals,
cardiovascular
Cyclic-AMP.
20
change
in (rat),
317
drugs
desensitization
effects
of,
95
activity,
studies
154
in
cells
agonist-antagonist,
cardiac
293
desensitization
nylate
receptors
dopamine
on,
hydroxylase
effect
agonist-induced
Cerebral
in,
53
P effect
tyrosine
201
Catecholamine(s)
human,
cells
responsiveness
Cyclazocine
Oxygen
drugs,
and,
substance
system
yohimbine
to neuroleptic
dopamine-sensitive
205
192
calcium
See
morphine-like
of
effects
dopamine-sensitive
pharmacological
54
dopamine
and,
effect,
glucagon,
188
contractility,
P, 99, 109
cardiac,
glucagon
consumption.
Cardiovascular
Central
and
and
binding
to,
cellular
neurons
prefrontal
effects,
effects
dopamine-
62
dopamine
3H-ligand
293
subjective
Calcium
Capsaicin,
responand
neurons
62
respiration,
Calcium,
in,
pharmacological
dopamine
electrophysiological
on
and
mesocortical
cells
sensitive
318
cardiovascular
Coronary
characteristics
siveness
mesocortical
effects
55
in,
Butorphanol
agonist-antagonist,
257
55
frontal
96
on,
54
257
opioids,
levels,
3H-dopamine
230
site
effects
Buprenorphine,
to,
opiates,
microelectrophoretic
246
P
projection
intravenous
of midbrain,
substance
93
230
morphine
reticular
in,
morphine
neurones,
opioid
concentration
on
I
levels
of,
298
agonists
in rat
298
effect,
and
brain,
mesocortical
193
biochemical
antagonists
56
effects
system
characteristics,
55
on,
58
between,
59
rat
327
INDEX
biochemical
response
of, to physiological/pharmacological
Farah,
manip-
57
ulations,
involvement
function,
intracranial
activity,
stress,
opioid
Ganglia,
to
Ganglia
ACTH124,
61
61
basal.
5-hydroxytryptamine,
and,
acid
62
diethylamide
(LSD),
P,
action
with
other
dopamine
systems
(table),
and
pharmacological
characteristics
of, in cortex,
pharmacology
of,
60
on
and,
cortical/subcortical
cortex,
interaction,
discovery
and,
and
of
effect(s)
with
actions
of yohimbine,
response
to
footshock
Dopamine
to
the
nigrostriatal,
possible
showing
possible
sites
for
60
renin
secretion,
56
infusion
characteristics
of, in the
cells,
and
frontal
cortex,
pharmaco-
on,
kidney
sites
neurone.
Dorsal
root
potentials,
for
drug
interactions
with
drugs
dopaminergic
in cortex,
See
under
on,
neuronal
A. W.,
and
pathways
R. A. North.
Electroencephalogram,
Endocrine,
yohimbine
effects
effects
systems,
1657,
physiological
involved in, 285; (fig.),
Electrophysiology
neurones
evidence
for
(fig.),
artery
in nine
191
187
dogs
properties
of the
heart,
(table),
183
189
of anesthetized
dog
183
203
196
cyclase
R.,
and,
and
probe
195
David
for
Robertson.
study
studies
Kendall,
of the
Yohimbine:
A pharma-
a2-adrenoreceptor,
in animals,
Agonist-induced
receptor-linked
143
306
desensitization
adenylate
glucagon
of the
cyclase,
$-adrener-
5
286
of opioids,
analgesics,
219
and
glucagon
effects
to
263
effects,
glucagon
cAMP
in
formation
190
194
humans,
in,
199
on
influencing
factors,
mechanical
and
rate,
189
rate yohimbine
297
glucagon
response
glucagon
189
effects,
properties,
failure,
61
193
effects
differences
on,
properties
of,
189
147
in response
to glucagon,
193
Hippocampus
a physiological
role
of,
use
of
naloxone,
neuronal
organization
(fig.),
271
Esophagus
the
of
CAl
region,
schematic
representation
259
opioids
pharmacological
substance
effects
of substance
P concentration
Ethanol,
mesocortical
in,
dopamine
P,
104
in vitro
103
system
in vivo
response
to,
61
experiments,
259
experiments,
acid
Homovanillic
Ethylketazocine
258
(HVA),
dopamine
metabolite
in rat
brain,
56
Hormone
cardiovascular
effects,
discrimination
by rats
drugs
effects
T.
species
myenteric
(table),
(ta-
184
and,
addiction
electrical
57
Enkephalin
on
trabeculae
Heart
240
of opiate
on, 162
and
185
adenylate
contractility,
syndromes,
of fasting,
effects,
coupling,
gic
action
sites
on dopamine
dopamine
response
to,
muscle
188
and,
cological
Harden,
Drug(s)
.dopaminergic,
miscellaneous,
papillary
57
55
effects,
191
(table),
188
Michael
Neurone(s)
morphine
205
vascular
dopamine
GPA
201
dog
phosphorylation
Goldberg,
system
58
3H-,
horn
mesocortical
metabolism,
lipid
changes
renal
function
receptor
58
and
circulation,
of, into
protein
agents
and,
of dog
excretion,
peripheral
62
63
195
197
ion
Dopamine,
of
Dorsal
effect
N-unit,
drug
184
in natriuresis
and
renal
of dopaminergic
(fig.),
uptake,
158
contractility,
hemodynamic
receptor,
See
Duggan,
function
pulmonary
cortical
effects
action
on,
199
potential
maximal
prefrontal
system
of
influence
103
192
168
stress,
cyclase,
mesocortical.
Dopamine
(table),
of anesthetized
58
(fig.),
responsiveness
receptors
102;
muscle,
carbohydrate
intracellular
64
relationship
3H-,
88,
on
kidney
its
dopamine
interactions
synthesis,
98
of, 206
mechanical
-related
prefrontal
in,
181
desensitization
55
of, 54
of,
nigrostriatal
logical
102
160
smooth
by,
hemodynamics
anatomy
-sensitive
in (fig.),
198
ble),
cells,
239
vitro,
P concentration
in heart,
cardiac
unit,
circulation
distribution
in brain
(fig.),
and biochemical
characteristics
cortex, 54
sites
yohimbine
ions,
projection
-sensitive
P
in,
tract,
production
53
prefrontal
adenylate
in
substance
on,
cAMP
cardiac
cortex
-sensitive
of generalization
ganglia
substance
vascular
catalytic
53
prefrontal
receptors,
neurones
distribution
formation
57
mesocortical,
Basal
influence
cAMP,
calcium
respon-
62
diagram
depicting
cerebral
degree
Glucagon
mesocortical
siveness
monkeys,
tract
Genitourinary
61
neurons
comparison
181
304
spinal
peripheral;
yohimbine
morphine,
(table),
See
substance
62
62
schematic
midbrain,
on
Gastrointestinal
d-lysergic
circulation,
and
(table),
mesenteric,
nerves
61
lithium,
by rats
drugs
actions
inferior
lesions,
ethanol,
discrimination
Frog,
the
63
63
response
brain
63
and
87
of,
to other
63
self-stimulation,
locomotor
E. Glucagon
natriuresis
Fentanyl,
in
cognitive
Alfred
Fasting,
on
(table),
respiration,
294
and
304
293
regulation,
monkeys,
degree
of generalization
to other
fl-adrenergic
system
for
responsiveness,
tion
study
modification
in
nucleotide
receptor-linked
adenylate
cyclase,
model
of, 5
of;
synthesis,
by
mechanisms
6
unrelated
to reduc-
328
INDEX
Morphine
Hormone-continued
-specific
desensitization,
13
5-Hydroxytryptamine
action
mesocortical
dopamine
substance
P and,
response
Hypotension,
orthostatic;
system
response
discrimination
62
to,
effects
on,
148
Hypothalamus
substance
studies,
P effects
on,
yohimbine
olivary
on,
of opiates
concentration
103,
in,
in,
root
cells,
substance
103;
(fig.),
effects
of,
of raphe
of
and,
effects
104
105
Invertebrate
on,
action
nervous
agonists,
-like
drugs,
-like
119
effects,
system,
respiration,
in
by impulse
in slowly
301
analgesic
and
subjective
effects
and
morphine-like
laboratory
animals,
discriminative
relationship
between
45
in
system
brain
response
stem
to,
and
62
responses
of
lamina
V
spinal
230
of action,
294
intravenous
Paul
of
303
in humans
dopamine
Munson,
reduction
227
in man,
effects
microinjection
Motoneurones,
Kidney
(table),
mesocortical
sites
294
293
(fig.),
and,
effects
neurones,
cardiovascular
V neurone
afferents
effects,
and
neurone
232
of a lamina
subjective
by
V
lamina
(fig.),
agonist-antagonists
(table),
on
of
primary
subjective
266
Ketazocine
effects
236
230
inhibition
stimulus
opioid
and,
of excitation
-like
in, 88
system,
(fig.),
240
excitation
produced
pharmacological
266
235;
neurones
descending
105
P
acetylcholine
to other
300
conducting
in,
of, 229
of generalization
228
in man,
reduction
pharmacological
system,
potentials,
Renshaw
P
concentration
degree
effect
intravenous
249
small
substance
235
(fig.),
lesions,
304
gelatinosa,
reduction
P
substance
monkeys,
293
firing
148
microinjection
Intestine
large,
and
nervous
subjective,
P, 90
effects
nucleus,
spinal
in invertebrate
on
Inferior
limited
cardiovascular,
on dorsal
substance
Impotence,
(table),
in substantia
95
254
Immunochemistry,
potentials
and
effects
194
yohimbine
postsynaptic
by rats
drugs
to glucagon,
-neurohypophysis,
excitatory
supraspinal
118
Hypertension,
opioid
on
analgesia,
(5-HT)
Lewis,
opiates
tribute
to,
effect
on
firing
of, 226
3
Muscle
function
diabetes
effects
glucagon
and,
glucagon
effect
on,
renin
substance
effect,
smooth
186
P
substance
185
analogues,
on
in natriuresis
on
glucagon
of fasting,
secretion,
effect
on,
121
relationship,
structure-activity
187
P
a2-adrenoreceptor,
concentration
in,
effect on,
117
vascular
188
glucagon
98
163
action
on,
184
113
Nalbuphine
Levorphanol
action
on excitatory
motoneurones
Ligand
binding,
to
235
in rat
frontal
effects
dopamine
activity,
cortex,
and
agonists
glucagon
mesocortical
Locomotor
addiction
spinal
antagonists,
on,
system
involvement
partial
60
agonist,
response
to,
of mesocortical
in
with
dopamine
naloxone-sensitive
receptor
system
in,
on (fig.),
253
effects
studies,
in vivo
252
studies,
301
on
system,
partial
294
292
agonist,
subjective
opioids
in vitro
man,
Nalorphine
62
respiration,
interaction
294
317
effects,
cardiovascular
enkephalin
306
293
subjective
201
coeruleus
d-Lysergic
in animals,
system,
respiration,
56
63
Locus
studies
cardiovascular
dopamine
metabolism,
Lithium,
in
effects on
(fig.),
receptors
response
potentials
3H-
neuroleptic
Lipid
postsynaptic
317
effects,
in
300
man,
Naloxone
action
251
acid
diethylamide
response
to, 61
(LSD),
mesocortical
dopamine
on
excitatory
(fig.),
system
postsynaptic
pA2 of, in antagonizing
the
agonist-antagonists
Man,
yohimbine
Martin,
actions
William
Meperidine,
in,
147
R. Pharmacology
rat
Mesencephalon,
tail
squeeze
and
P
substance
283
of opioids,
tail
flick
concentration
test,
in,
dorsal
horn
ED5O,
in antagonizing
289
91
effect
lipid,
glucagon
glucagon
water,
yohimbine
Metabolite,
Midbrain,
Monoamine(s),
effects
effects
on,
P, role
substance
influence,
dopamine.
dorsal
raphe
transmitters
on,
201
pure
113
use
See Dopamine
metabolites
neurones
of, 250
cord,
234
and,
spinal
motoneurones
action
mouse
of narcotic
(table),
analgesic
and
analgesics
and
291
244
the
in man,
analgesic
in
rat
action
and
of narcotic
mouse
(table),
291
of,
296
293
antagonist,
subjective
161
in spinal
neurones
respiration,
201
in,
in
on
pupils,
carbohydrate,
analgesic
in the
agonist-antagonists
Metabolism
potentials
235
313
effects,
in man,
in determination
Naltrexone
effects
pupils,
on
in
man,
302
of
296
functional
role
of
enkephalins,
271
329
INDEX
respiration,
pure
Nucleus
293
subjective
effects,
in
antagonist
Nucleus
activity
effects
of
290
against,
N-unit,
in,
of stria
terminals,
glucagon
256
and
pretectal
area,
microinjection
of
249
opioid effects,
effect
on,
256
197
Opiate(s)
in man,
295
action
in
296
administration
dogs,
potency
dogs
of
Nervous
of,
in
(table),
Natriuresis
producing
and
miosia
analgesia
in
man
function
in,
187
and
296
fasting,
opioid
glucagon
Central
invertebrate.
effect
nervous
See
See
peripheral.
kidney
on
Peripheral
nervous
system
system
P
pharmacological
ejection
systemic,
221
on,
relationship,
medulla,
substance
P and
acetylcholine
under
Dopamine
effects
119
on,
effect
neuron
of
spinal
226
(fig.),
by
animals
opiate
and
action
animals
with
226
intact
CNS,
comparison
of
spontaneous
and
opiates
inhibition
of, opiates
microphoretically
and,
afferent
single
neurones,
spinal
reflexes,
237
267
267
opiate effect
on
response
in culture
of (fig.),
268
excitation
reduced
of,
spinal,
response
to
by
effects,
263;
effect
on
(fig.),
opiate
raphe.
See under
Brain
intravenous
opiates
morphine
in
normorphine
brain
and
stem,
264
firing
of reticular
firing
of
peptides,
effects
morphine,
postsynaptic
descending
firing
levorphanol,
potentials
inhibition
and
270
in
of,
(fig.),
on
excitatory
235
Opiate
231
and
opioid
opiates,
opioids,
summary
Neuropeptide(s),
peripheral;
Neuropathy,
232
yohimbine
with
effects
other,
on,
enhanced
by yohimbine,
in central
and
in vitro
Neurotransmitters,
classical,
Nociception,
substance
Norepinephrine,
124
148
effect
R. A.
See
synthesis,
siveness
on
Duggan
by mechanisms
with
on
myenteric
and
152
influence
substance
turnover,
149
neurones
North,
(fig.),
(table),
unrelated
of
to,
6
hormonal
(PAG)
matter,
249
285
261
and
261
synaptic
excitation
of
dorsal
horn
neurones,
in vivo
of,
for
70
(table),
70
localization
on
spinal
of, 70
neurones
and,
addiction
studies,
direct
man,
in vitro,
239
242
cyclaae
305
305
154
of
chronic
respon-
(table),
antagonists
and
of flexor
abstinence
relative
modification
229
248
properties,
agonist-antagonists,
in suppression
219
in;
and,
agonists
P, 117
in vivo
263
neurones
system
adenylate
in
on,
123
influence
reduction
(table),
yohimbine
interaction
P and,
yohimbine
Normorphine
systems
tissues,
spinal
grey
differences,
firing
in animals,
peripheral
horn
246
receptors
actions
P interrelation
release
Neurotransmitter
and,
studies,
microscopic
Opioid(s)
245
of effects,
substance
of dorsal
neuronal
conditions
of opioids,
239
247
administered,
nervous
on
labeled
225
microelectrophoresis
actions
on, in vitro,
neurone
225
of, in periaqueductal
autoradiography
intravenous
268
(fig.),
gelatinosa
234
of
and
and,
and,
stimulation
naloxone
neurones
substantia
228
neurones
opioids,
effects
247
on,
in
neurones
inhibition
pulp
peripheral
of,
immature
257
spinal
non-opiate
firing
of
motoneurones,
spontaneous
of
culture
255
microinjection
spinal
actions
in
conductance
cortex,
of
tooth
stem
and
264
222
supraspinal
230
enkephalin
264
effects,
opioid
neurones,
microelectrophoretically
between,
opiates
and
of
232
(fig.),
263
transmission
afferent,
single,
of
recording
primary
reticular,
morphine
microinjection
intracellular
myenteric,
intravenous
265
270
ganglia,
firing
V
lamina
animals
229
240
cerebral
synaptic
spinal
on
basal
action,
in
system,
intravenous
effects
in culture,
nervous
298
response
(fig.),
peptides,
central
270
potassium
234
administered
neurones
transmission,
assemblies,
increase
excitation
297
horn
264
of consciousness,
synaptic
immature
opiate
neuroeffector
primary
229
of,
225
firing,
synaptic
supraspinal
intact
transmission,
neuronal
229
on,
intravenous
with
afferents,
244
and,
naloxone
in primary
with
changes,
dorsal
on
on
levels
impulses
298
of,
animals
junctional
excitation
opiate
222
micropipettes,
by,
of actions
autonomic
horn
and
222
vitro,
from
electroencephalogram
on
comparisons
116
See
mesocortical.
spinal,
in
induced
effects
88
with
anatomy
221
of tissues
pressure
Neuron(e)
in
221
convulsions
actions
structure-activity
dorsal
247
analgesics
87
in,
dopamine,
267
and,
perfusion
nervous
culture,
in
222
iontophoretic,
system
Invertebrate
concentration
adrenal
neurones
microelectrophoretic,
See
substance
immature
microinjection,
system
central.
on
from micropipettes,
292
respiration,
relative
Nucleotide
effects,
on
pupils
North,
opioid
Edinger-Westphal
opiates
302
man,
analgesics
Narcotic
accumbens,
Nucleus
313
antagonist,
spinal
potency
in
dog
antagonists
reflex
and
suppression
nondependent
(table),
and
and
precipitation
morphine
dependent
316
of, in inhibition
of binding
of p. #{244},
and
s ligands
316
and,
suppression
of nociceptive
responses
and
reflexes
330
INDEX
schematic
Opioid(s)-continued
in animals,
analgesics
relative
nociceptice
of, in producing
potency
reflexes
in animals
(table),
analgesia
with
288
classification
317
identification
partial
effect
of
prototypic
agonists,
on
and
317
brain,
monkey
tissues
in
retina
substitution
in spinal
cord
(mouse)
in vitro
labeling,
306
dm58-tolerance
of,
and
precipitation
spinal
and,
suppression
and
ent
243
precipitation
monkeys
and
of abstinence
opioid
men
and
cyclazocine-dependent
dogs
receptors
and,
pects,
relationship,
316
discriminative
pharmacological
as-
stimulus
properties,
neurones,
pathways,
projections
agonists,
studies,
in vivo
258
(table),
firing
of spinal
administered,
248
neurones,
232
in man,
abstinence
on
238;
consumption,
Pancreas,
administered
in substantia
gela-
238
(fig.),
single
270
neurones,
cord,
242
spontaneous
in man,
glucagon
yohimbe,
of, 143
302
effect,
247
193
on
rat
squeeze
tail
and
effects,
excitation
horn
See
opioid.
synaptic
with,
of dorsal
124
285;
dualism,
horn
neurones,
role
(fig.),
afferent
flick
from
test,
289
301
cord,
tract,
Opioid
schematic
besides
illustration
(fig.),
126
P, 104
substance
peptide(s)
as transmitters
or modulators
in central
and
peripheral
nervous
86
grey
Peripheral
nervous
matter
(PAG),
microinjection
of opiates
in,
249
system
opiates
of, 283
primary
tail
in man,
of spinal
Periaqueductal
286
287
dependence,
in extracts
292
in gastrointestinal
248
225
and
P interaction
physical
alkaloid
294
respiration,
system,
pharmacological
112
principal
317
effects
in dorsal
administered,
firing
by,
yohimbine,
effects,
cardiovascular
237
putative
305
Peptide(s)
nuclei,
spinal
reflexes
and,
psychological
effects
cardiac,
P secretion
substance
subjective
in trigeminal
analgesia,
(table),
293
Pentazocine
of
pharmacology
80
300
respiration,
agonist-antagonist,
substance
316
(table),
syndrome
effects
bark
[Metlenkephalinamide
in spinal
sites,
254
Pausinystoiia
peptide(s)
on
binding
251
255
cortex,
257
function
79
37
effects
ganglia,
effects
(fig.),
309
subjective
Oxygen
of, and
tinosa,
(rat)
263
Oxilorphan,
of
agonist-
313
by autoradiography
withdrawal
252
effects
in brain
properties,
Oxalorphan,
microelectrophoresis
cerebral
agonists,
309
78
312
of, with
subjective
221
studies,
competitive
agonists,
312
receptor,
thalamus,
221
studies,
agonists,
80
studies
coeruleus
in vitro
of (fig.),
partial
reaction,
localization
259
experiments,
basal
and
“opiatergic”
reinforcing
of, 219
preparations,
in vivo
of opioid
hypothalamus,
vivo
in vitro
theory
subtypes
302
42
245
experiments,
of, 75
localization
partial
hippocampus
in vitro
73
315
in function,
relationship
in animals,
electrophysiology
75
69
“opiatergic”
M
stimuli,
spinal
on
and
35
36
testing,
discriminative
304
terminals
effects,
in
studies,
effects
properties,
on
Peripheral
the
spinal
cord
and.
232
Pernow,
neuronal
P
substance
239
and,
300
transmitters
distribution
vascular
Bengt.
261
261
in, 98
system,
glucagon
P,
Substance
effects,
183
85
$-[_-5-Phenyl-9-Methyl-2’-hydroxy-2-methyl-6,7-benzomorphine
receptor(s)
antagonists,
future
(GPA
312
autoradiography,
differentiation
hypothetical,
schematic
and
labeling
transport
use
conditions
77
of “mu”
and
Phosphorus,
of, 78
for
(table),
73
Platelets,
78
Pons-medulla,
Potassium,
of,
topographic
oblique
1657),
Phosphodiesterase
69
modification
in vitro
axonal
film,
role,
‘C receptor,
testing,
psychic,
effects
behavioral
33
physical,
73
method,
localization
labeling,
steric
(table),
dependence
mixed
method,
ligand-receptor
antagonists,
sites,
74
72; 73
autoradiographic
in morphine-depend-
307
binding
71
74
multiple
308
studies,
reflexes
in vivo
of, 242
specificity
(fig.),
coverslip
microscopic
adequacy
(fig.),
71
tritium-sensitive
308
(table),
(rat)
76
(fig.),
“fixed”
nerve
76
(fig.),
emulsion-coated
studies,
vagus
(fig.),
(rat)
299
311
autoradiography
75
monkey
autoradiography
regulation,
and
tolerance
and,
agonists
(fig.),
receptor
and
in
antagonists
L
view
by
in
317
temperature
suppression
locus
shown
in caudate-putamen
agonist-antagonist,
in
oblique
in brain,
287
“delta”
model
drawing
sites,
(fig.),
of (fig.),
310
312
Primary
electrical
addiction
inhibitors,
glucagon
yohimbine
influence
raphe
glucagon
afferent
effect
nuclei
effect
studies
effect
on
in animals,
on
excretion
on,
heart
response
of, 188
161
of, 250
on excretion
of,
terminals
stimulation
of terminals
of, 240
188
306
to
glucagon,
195
331
INDEX
opioids
and,
release
239
from,
role,
Profadol
addiction
studies
partial
in animals,
Propiram,
partial
Protein
carboxymethylation,
phosphorylation,
317
dopamine
autoreceptor
and,
glucagon
See
circulation.
under
and,
Circulation
analgesics,
neurones.
Spinal
reflexes
in comparison
e agonist
to morphine
(table),
and
297
substance
Radioligand
binding
studies,
himbine
Raphe
in,
neurone(s).
Rat,
opioid
dog,
224
frog,
223
agonist
Receptor
coupling,
a2-adrenoreceptor
definition,
use
of yo-
See
under
on
spinal
and
Brain
antagonist,
in vitro,
239
nomenclature,
glucagon
effect
antagonists
opioid
peptides,
dopamine.
See
Dopamine
concentration
Opiate
receptors
opioid.
See
Opioid
receptors
Renal
ion
Renin
secretion,
excretion,
Renshaw
morphine
effect
on,
dopamine
on
kidney
effects
on,
228
function,
188
and,
acid
293
diprenorphine,
293
ethylketazocine,
ketazocine,
127
antagonists,
121
293
brain
nalorphine,
292
capsaicin
293
narcotic
analgesics,
oxalorphan,
293
and
pharmacological
effects
opioid
in,
receptors
in
H. See
(rat)
Bannon
P,
central
nervous
111
gland(s),
Salivary
secretion
substance
analogues,
with
P,
substance
Self-stimulation,
by,
tract,
respiratory
117
effect
and
Schuster,
involvement
of yohimbine,
of
167
cord
actions,
opioid
peptides
opioid
receptors
222
33
mesocortical
dopamine
in
(mouse)
transmitters
substance
in,
in,
242
(fig.),
P
concentration
pharmacological
74
and,
93
actions
96
effects,
97
107
95
hypothalamus-neurohypophysis,
system,
107
of, 86
and
peripheral
nerves,
5-hydroxytryptamine
inactivation,
95
95
area,
and,
as undecapeptide,
90
immunochemistry,
on,
103
88
identification
in,
(table),
98
86
pharmacological
ganglia
232
102;
99
stem,
extraction
opioids
88,
on
brain
vascular
function
92
of
coexistence
tract,
110
organs,
system,
striato-nigral
opiate
in gastrointestinal
system,
tract,
cortex,
action
aspects
87
circulation,
in, 63
Serotonin-related
putative
111
111
intracranial,
system
functional
peptides
nervous
visual
relationship,
R. See Woolverton
(table),
107
various
structure-activity
Schuster,
Charles
and
other
gastrointestinal
122
on,
90;
115
tissue,
effect
in,
113
circulation,
P
substance
108
of,
distribution
143
53
P secretion
effects
distribution
neurotransmitters
peripheral
Salivary
of,
system,
86
comparison
76
Roth,
117
119
and Robertson,
and
96
99
and,
administration
degradation,
(fig.),
from,
on,
central
111
110
David. See Goldberg
Robert
P,
of substance
P distribution
Robertson,
substance
126
effects
classical
hyperreactivity
109
and,
release
choleresis,
tract
substance
99,
stem,
chemistry,
292
pentazocine,
Respiratory
292
111
123
vasodilatation
catecholamines
293
naltrexone,
in, 63
of, 87
biosynthesis,
nalbuphine,
naloxone,
system
95
89
of,
antagonism,
bioassay
293
on,
121
antidromic
293
and,
effects
analogues,
292
effects
119
composition,
analgesic
cyclazocine,
P
substance
hyperreactivity
amino
butorphanol,
60
to,
dopamine
P, 85
airway
293
response
area,
acetylcholine
of
Spinal
104
of mesocortical
Substance
188
effect
N-allylnormetazocine,
Secretion,
103
effects,
involvement
Striato-nigral
glucagon
glucagon
cells,
footshock,
Respiration
Roth,
in,
pharmacological
receptors
See
Retina,
243
Stress
opiate.
airway
and,
225
P
substance
286
Receptor(s)
effects
opioid
196
on,
223
Stomach
stem
neurones
spinal
224
rat,
89
148
actions
Receptor
P
Neuron(s),
effects
man,
Radioimmunoassay,
See
223
cat,
x agonist,
antagonists,
P, 234
Spinal
opiate
narcotic
234
substance
295
analgesics,
232
monoamines,
60
203
of
narcotic
233
acids,
amino
Pupils
effects
in
acetylcholine,
agonist,
Protein
Pulmonary
transmitters
306
317
agonist,
96
127
126
concentration
118
89
in, 98
104
of,

of yohimbine on, in man Age, effect on response of heart to

Transcription

Similar documents